DK1860101T3 - Tartrat salt af isofagomin og fremgangsmåder til anvendelse deraf - Google Patents

Tartrat salt af isofagomin og fremgangsmåder til anvendelse deraf

Info

Publication number
DK1860101T3
DK1860101T3 DK07252109.9T DK07252109T DK1860101T3 DK 1860101 T3 DK1860101 T3 DK 1860101T3 DK 07252109 T DK07252109 T DK 07252109T DK 1860101 T3 DK1860101 T3 DK 1860101T3
Authority
DK
Denmark
Prior art keywords
isophagomine
methods
tartrate salt
salt
gaucher disease
Prior art date
Application number
DK07252109.9T
Other languages
Danish (da)
English (en)
Inventor
Benjamin Mugrage
David Palling
Philip J Rybczynski
Kamlesh A Sheth
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Application granted granted Critical
Publication of DK1860101T3 publication Critical patent/DK1860101T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
DK07252109.9T 2006-05-24 2007-05-23 Tartrat salt af isofagomin og fremgangsmåder til anvendelse deraf DK1860101T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80802006P 2006-05-24 2006-05-24
US89071907P 2007-02-20 2007-02-20

Publications (1)

Publication Number Publication Date
DK1860101T3 true DK1860101T3 (da) 2011-07-25

Family

ID=38462442

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07252109.9T DK1860101T3 (da) 2006-05-24 2007-05-23 Tartrat salt af isofagomin og fremgangsmåder til anvendelse deraf

Country Status (14)

Country Link
US (2) US7501439B2 (enExample)
EP (1) EP1860101B1 (enExample)
JP (1) JP5292605B2 (enExample)
AT (1) ATE504570T1 (enExample)
AU (1) AU2007202359B2 (enExample)
BR (1) BRPI0706114A2 (enExample)
CA (1) CA2590122C (enExample)
DE (1) DE602007013648D1 (enExample)
DK (1) DK1860101T3 (enExample)
IL (1) IL183415A (enExample)
MX (1) MX2007006175A (enExample)
PL (1) PL1860101T3 (enExample)
PT (1) PT1860101E (enExample)
WO (1) WO2007140212A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006254796B2 (en) * 2005-06-08 2012-08-16 Amicus Therapeutics, Inc. Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes
BRPI0713442A2 (pt) 2006-06-23 2012-03-06 Amicus Therapeutics, Inc. Método para o tratamento de desrodens neurológicas, pelo aumento da atividade de b-glicocerebrosidase
WO2008144773A1 (en) 2007-05-22 2008-11-27 Amicus Therapeutics, Inc. New method for preparing isofagomine and its derivatives
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
AU2009314447A1 (en) * 2008-11-14 2010-05-20 Neuraltus Pharmaceuticals, Inc. Compositions and methods for the treatment of altered alpha-synuclein function
CN109172813B (zh) 2009-07-28 2022-09-02 武田药品工业株式会社 用于治疗戈谢病的组合物和方法
RU2608520C2 (ru) * 2009-10-19 2017-01-19 Амикус Терапьютикс, Инк. Новые композиции для предупреждения и/или лечения лизосомных болезней накопления
LT2490532T (lt) 2009-10-19 2017-03-27 Amicus Therapeutics, Inc. Naujos kompozicijos centrinės nervų sistemos degeneratyvinių sutrikimų profilaktikai ir (arba) gydymui
DK2707101T3 (da) 2011-05-12 2019-05-13 Proteostasis Therapeutics Inc Proteostaseregulatorer
WO2012177997A1 (en) 2011-06-22 2012-12-27 The General Hospital Corporation Treatment of proteinopathies
AU2013202368B2 (en) 2012-01-25 2016-06-16 Proteostasis Therapeutics, Inc. Proteasome activity modulating compounds
AU2013225816B2 (en) 2012-03-02 2017-10-26 Takeda Pharmaceutical Company Limited Compositions and methods for treating Type III Gaucher Disease
ES2924829T3 (es) 2012-03-27 2022-10-11 Amicus Therapeutics Inc Compuestos novedosos para prevenir y/o tratar tesaurismosis lisosómicas y/o trastornos degenerativos del sistema nervioso central
JP2015512913A (ja) 2012-03-28 2015-04-30 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ グルコセレブロシダーゼ活性剤として有用なサリチル酸誘導体
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
DE102017103346A1 (de) * 2017-02-17 2018-08-23 Lts Lohmann Therapie-Systeme Ag Strukturierte orodispergierbare Filme
CN111278439A (zh) * 2017-10-26 2020-06-12 夏尔人类遗传性治疗公司 包含葡萄糖脑苷脂酶和异烟肼的调配物
MX2020014082A (es) 2018-06-27 2021-04-13 Proteostasis Therapeutics Inc Compuestos que mejoran la actividad del proteasoma.
JP7551087B2 (ja) 2018-06-27 2024-09-17 キネタ, インコーポレイテッド プロテアソーム活性増強化合物
WO2020023390A1 (en) 2018-07-25 2020-01-30 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
JP7642561B2 (ja) * 2019-04-25 2025-03-10 武田薬品工業株式会社 イソファゴミン塩、その使用方法および製剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844102A (en) * 1994-07-07 1998-12-01 University Of Maryland Baltimore County Glycohydrolase inhibitors, their preparation and use thereof
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A

Also Published As

Publication number Publication date
US20070281975A1 (en) 2007-12-06
EP1860101B1 (en) 2011-04-06
WO2007140212A2 (en) 2007-12-06
JP5292605B2 (ja) 2013-09-18
AU2007202359B2 (en) 2012-02-16
IL183415A0 (en) 2007-09-20
US7863453B2 (en) 2011-01-04
CA2590122A1 (en) 2007-11-24
BRPI0706114A2 (pt) 2008-11-18
US20090176830A1 (en) 2009-07-09
DE602007013648D1 (de) 2011-05-19
CA2590122C (en) 2015-03-31
MX2007006175A (es) 2009-02-16
US7501439B2 (en) 2009-03-10
PT1860101E (pt) 2011-07-12
ATE504570T1 (de) 2011-04-15
EP1860101A1 (en) 2007-11-28
JP2007314540A (ja) 2007-12-06
IL183415A (en) 2012-03-29
PL1860101T3 (pl) 2011-10-31
WO2007140212A3 (en) 2008-12-24
AU2007202359A1 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
DK1860101T3 (da) Tartrat salt af isofagomin og fremgangsmåder til anvendelse deraf
ATE532518T1 (de) Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
NO20070470L (no) Sammensetninger og fremgangsmater for behandling av dyslipidemi
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
EA201070699A1 (ru) Композиции 3-(6-(1-2,2-дифторбензо[d][1,3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
EA200702208A1 (ru) Ингибиторы дипептидилпептидазы-iv
ATE447559T1 (de) 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3- carboxamid derivate als mek inhibitoren zur behandlung von hyperproliferativen erkrankungen
NO20081905L (no) Benzotiazolcyklobutylaminderivater og deres anvendelse som histamin-3-reseptorligander
EP1916964A4 (en) IMPLANTS AND METHODS FOR THE REPAIR, REPLACEMENT AND TREATMENT OF JOINT DISEASES
ATE530519T1 (de) Cyclobutylaminderivate
DK1704146T3 (da) Stereoisomere forbindelser og fremgangsmåder til behandling af mave-tarm- og centralnervesystemlidelser
DK1617834T3 (da) Anvendelse af en farmaceutisk sammensætning indeholdende mælkesyre eller lactat og kalium til behandling af hjerneödem eller hjerneskade
DK1720848T3 (da) Derivater af alkylpiperazin- og alkylhomopiperazincarboxylater, fremgangsmåde til fremstilling heraf og anvendelse heraf som inhibitorer af enzymet FAAH
PL1960379T3 (pl) Pochodne N-(1-alkilo-2-fenyloetylo)-karboksamidu i ich zastosowanie jako fungicydów
DK1641456T3 (da) Gaboxadol til behandling af depression og andre affektive lidelser
NO20054876D0 (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser
DK1901731T3 (da) Niacinreceptoragonister, sammensætninger indeholdende sådanne forbindelser og fremgangsmåder til behandling
DE602006013271D1 (de) Verfahren zur herstellung von 4-(phenoxy-5-methyl-pyrimidin-4-yloxy)piperidin-1-carboxylsäure-derivaten und damit zusammenhängenden verbindungen
UA88481C2 (ru) Донепезила фумарат, пригодный для получения фармацевтических композиций
DE60223718D1 (de) Verwendung von norepinephrin wiederaufnahmehemmern zur behandlung von kognitiven störungen
ATE439831T1 (de) Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendung
DK1856063T3 (da) 5-phenyl-pentansyrederivater som matrix- metalloproteinaseinhibitorer til behandlingen af astma og andre sygdomme
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
BRPI0519093A2 (pt) mÉtodo para preparaÇço de amlodipina opticamente ativa e composto
DK2099501T3 (da) 2,6-diphenyl-4,8-diazoadamantan-1-on og derivater deraf, fremgangsmåde til fremstilling og anvendelse til formuleringen af opløsninger med steriliserende og desinficerende virkning